Drugs for GIST (Gastrointestinal Stromal Tumor)
Find financial assistance programs available for GIST drugs.
Ayvakit (avapritinib) Tablets
Drug company: Blueprint Medicines
Ayvakit is a tyrosine kinase inhibitor used for the treatment
of patients with unresectable or metastatic gastrointestinal
stromal tumor (GIST) harboring a PDGFRA exon 18 mutation,
including PDGFRA D842V mutation.
Blueprint Medicines offers 5 financial assistance programs
for patients who have been prescribed Ayvakit:
YourBlueprint Co-Pay Assistance Program
Eligible patients who have private or commercial insurance
may pay as little as $0 per prescription of Ayvakit.
YourBlueprint Patient Assistance Program
Patients who are uninsured, or who have limited insurance,
may be eligible to receive Ayvakit for free. Patients
must reside in the United States and meet the financial
Eligible patients may be able to receive a 15-day supply of
medication at no cost through this program while waiting to
get their insurance coverage.
Coverage Interruption Program
Patients who change their insurance or have a temporary
interruption in their insurance coverage may be eligible to get
a temporary no-cost supply of the medication.
Ayvakit Dose Exchange Program
Patients who had their dose of Ayvakit adjusted by their
doctor can trade their remaining medication for the new
dose at no cost.
Gleevec (imatinib mesylate) Tablets
Drug company: Novartis
Gleevec is a kinase inhibitor used for the treatment of
patients with Kit (CD117)-positive unresectable, recurrent
and/or metastatic GIST, and as an adjuvant treatment.
Novartis Patient Assistance NOW Oncology offers 3 financial
assistance programs for patients using Gleevec:
Gleevec Patient Support Program
This program offers patient counselors, educational information,
and financial assistance resources, such as the Gleevec $10 Co-Pay Card.
Novartis Oncology Universal Co-pay Program
Patients with private insurance may pay only $10 for a
30-day supply of Gleevec, with a maximum of $10,630 for a
30-day supply and up to an annual maximum of $30,000.
Novartis Patient Assistance Foundation
Patients who are experiencing financial hardship and have
limited or no public or private prescription coverage may be
able to receive Gleevec for free through the Novartis Patient
Assistance Foundation. To be eligible for financial assistance,
the patient must be a US citizen and must provide
proof of income that meets the financial eligibility requirements.
Eligible patients may receive Gleevec for free until
prescription drug coverage becomes available to them.
Qinlock (ripretinib) Tablets
Drug company: Deciphera
Qinlock is a kinase inhibitor used for the treatment of adults
with advanced GIST who have received 3 or more previous
kinase inhibitors, including imatinib.
Deciphera offers 2 financial assistance programs for patients
who have been prescribed Qinlock:
Commercial Copay Program
This program will cover all out-of-pocket drug costs so that
eligible patients who have commercial or private insurance
pay as little as $0 copay.
Patient Assistance Program
Eligible patients who do not have insurance, or whose coverage
does not cover the cost of Qinlock, may qualify to
receive Qinlock for free through this program.
Stivarga (regorafenib) Tablets
Drug company: Bayer
Stivarga is a kinase inhibitor used for the treatment of
patients with locally advanced, unresectable, or metastatic
GIST after treatment with imatinib or sunitinib malate.
Bayer offers 2 financial assistance programs for patients
STIVARGA $0 Co-Pay Program
Through this program, patients with private insurance will have a $0 copay for Stivarga, up to $25,000 per patient annually.
Bayer US Patient Assistance Foundation
This foundation provides free medicine for patients who are
prescribed a Bayer medication and are uninsured or underinsured
and meet certain eligibility criteria.
Sutent (sunitinib malate) Capsules
Drug company: Pfizer
Sutent is a kinase inhibitor used for the treatment of patients
Pfizer Oncology Together offers 2 financial assistance programs
for patients using Sutent:
Pfizer Oncology Together Co-Pay Savings Program
This Pfizer program assists eligible patients with private
insurance so that their copay for Sutent is $0 monthly, with
a maximum savings of up to $25,000 annually.
Pfizer Patient Assistance Program
This program serves patients who are either uninsured or
those with government insurance. Uninsured patients may
qualify to receive Sutent for free or at a savings. Eligible
patients with government insurance who cannot find independent
charitable foundation support may receive Sutent
Table. Drugs Prescribed for GIST (Gastrointestestinal Stromal Tumor)
- Drug name (generic name)
- Drug company
- Patient support services
Drug name (generic name)
- Qinlock (ripretinib) Tablets
- Treatment of adults with
advanced GIST who have
received 3 or more kinase
inhibitors, including imatinib
Patient support services
- Commercial Copay Program
Patient Assistance Program
Last modified: March 21, 2022